ArticleScience signaling2019
Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance.
Article in Science signaling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 71 citations in OpenAlex.
- Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial.The oncologist · 2020Trial
- Reframing cancer therapy through tumor plasticity.Nature cancer · 2026Review
- Dissecting residual disease in spheroids reveals pan-cancer persistence signatures and a therapeutic window for oncolytic viruses.Molecular therapy. Oncology · 2026Article
- Mitochondria related gene signature serves as prognosis prediction and risk stratification of cholangiocarcinoma.Translational cancer research · 2026Article
- Mitochondrial geneTranslational cancer research · 2026Article
- Dissecting Cancer Metabolism and Therapeutic Resistance Using In Vitro Platforms.Advances in experimental medicine and biology · 2026Review
- Divergent transcriptional programs and constrained metabolic states reveal selective metabolic dependencies in chemoresistant luminal breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2026Article
- Metabolic adaptations in cancer progression.Physiological reviews · 2026Review
- Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer.Oncogenesis · 2025Article
- Cancer cell plasticity and therapeutic resistance: mechanisms, crosstalk, and translational perspectives.Hereditas · 2025Review
- Resistance to neoadjuvant chemotherapy in breast cancers: a metabolic perspective.Journal of experimental & clinical cancer research : CR · 2025Review
- Pisces: A multi-modal data augmentation approach for drug combination synergy prediction.Cell genomics · 2025Article
- Breaking the Resistance: Photodynamic Therapy in Cancer Stem Cell-Driven Tumorigenesis.Pharmaceutics · 2025Review
- Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies.Frontiers in pharmacology · 2025Review
- Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.Nature reviews. Cancer · 2024Review
- Purinergic CaCancers · 2024Article
- Optical imaging reveals chemotherapy-induced metabolic reprogramming of residual disease and recurrence.Science advances · 2024Article
- Purinergic CabioRxiv : the preprint server for biology · 2024Article
- Self-Reinforced Bimetallic Mito-Jammer for CaAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers.Breast cancer research : BCR · 2024Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 8 institutions in 4 countries.
Funding
Abstract
Metastable phenotypic state transitions in cancer cells can lead to the development of transient adaptive resistance or tolerance to chemotherapy. Here, we report that the acquisition of a phenotype marked by increased abundance of CD44 (CD44
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.